Curematch Co-founders Study the molecular Alterations of Genes to Develop Personalized Cancer Therapy Options

CureMatch, a Serra Capital III portfolio company, has recently published a study in the journal of Cancer Biology & Therapy. CureMatch is a digital health company focused on personalized medicine and combination therapy in oncology.

The study conducted by CureMatch highlighted the role of a specific molecular mutation in eosinophilic cystitis, and how their methods might better treat this type of condition. 

Source: http://www.prnewswire.com/news-releases/curematch-co-founders-study-the-molecular-alterations-of-genes-to-develop-personalized-cancer-therapy-options-300516362.html